Trial of curcumin in advanced pancreatic cancer

Bachmeier B. Kunnumakkara A. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Milacic V. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.

Sahu R. Glienke W. Cancer Investig. Ali S. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of mir and mir expression by curcumin or its analogue CDF. Yang C. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through janus kinase-STAT3 signalling pathway.

Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the Nf-kappaB transcription factor. Basha R. Cao L. Curcumin inhibits hypoxia-induced epithelialmesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway. Parsons H. The effects of curcumin diferuloylmethane on body composition of patients with advanced pancreatic cancer.

Sahebkar A. Curcumin: A natural multitarget treatment for pancreatic cancer. Cancer Ther. Yarla N. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Cancer Biol. Luthra P. Prospective of curcumin, a pleiotropic signalling molecule from curcuma longa in the treatment of glioblastoma.

Tsai C. Food Chem. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Diaz Osterman C. Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis. Zhao Z. Azimi H. Potential new pharmacological agents derived from medicinal plants for the treatment of pancreatic cancer.

Sinha D. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Drug Targets. Lao C. Dose escalation of a curcuminoid formulation. BMC Complement. Vareed S. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Cheng A. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

Anticancer Res. Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Bisht S. Antony B. A pilot cross-over study to evaluate human oral bioavailability of BCMCG biocurcumax , a novel bioenhanced preparation of curcumin. Indian J. Shaikh J. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer.

Anand P. Design of curcumin-loaded plga nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo.

Sasaki H. Innovative preparation of curcumin for improved oral bioavailability. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother. Kesharwani P. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. Colloids Surf. B Biointerfaces. Margulis K. Active curcumin nanoparticles formed from a volatile microemulsion template.

B Mater. Howells L. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT colorectal cancer cells in vitro and in vivo. Jutooru I. Inhibition of NfkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.

Youns M. Upregulation of extrinsic apoptotic pathway in curcumin-mediated antiproliferative effect on human pancreatic carcinogenesis. Two patients showed clinical biological activity. No toxicities were observed. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Curcumin, a yellow substance extracted from the plant Curcuma longa, is commonly used as a food additive. It is a natural anti-inflammatory compound and has shown anti-tumor activity in the laboratory.

During this study, you will receive much higher doses of curcumin than can be obtained from the diet. During the study, you will receive curcumin by mouth every day. You will be required to take up to 16 pills per day each morning. Every 8-week period you take curcumin is considered a "course" of treatment. The number of courses you receive depends on how you are responding to treatment. You can continue treatment as long as the disease does not get worse. If the disease gets worse or you experience any intolerable side effects, you will be taken off the study and your doctor will discuss other treatment options with you.

You will be given a questionnaire to complete at the beginning of the study and once a week while you are on therapy to help the medical staff understand how the different symptoms from your disease are affecting you. This questionnaire, which should take about 5 minutes to complete, can be done over the telephone or with the help of one of the study staff during your visits. This is an investigational study. Curcumin is a commercially available substance, which is commonly used as a food additive.

Up to 50 participants will take part in this study. All will be enrolled at M. Drug: Curcumin Starting dose 8 gm orally per day for 8 weeks.

Patients with grade IV toxicity will discontinue treatments. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. Search for terms. Save this study.

Warning You have reached the maximum number of saved studies Trial of Curcumin in Advanced Pancreatic Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.

Federal Government. Read our disclaimer for details. Results First Posted : August 28, Last Update Posted : August 28, Description Number of participants followed from baseline date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.